Enliven Therapeutics Inc. Total Assets
Enliven Therapeutics Inc. total assets. Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) holds total assets worth $910.22 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ELVN company net worth for the company's overall valuation and market capitalisation.
Total Assets of Enliven Therapeutics Inc. (2017–2025)
Total assets of Enliven Therapeutics Inc. from 2017 to 2025. This chart illustrates how Enliven Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See today's stock price for Enliven Therapeutics Inc. for real-time trading data and today's change.
Enliven Therapeutics Inc. - Asset Composition Analysis
Enliven Therapeutics Inc. Total Assets Breakdown (December 2025)
Enliven Therapeutics Inc. total assets breakdown as of December 2025. Enliven Therapeutics Inc.'s total assets of $910.22 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Enliven Therapeutics Inc. working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enliven Therapeutics Inc.'s current assets represent 99.7% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, down from 94.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Enliven Therapeutics Inc. Competitors by Total Assets
Key competitors of Enliven Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Enliven Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 64.07 | 32.58 | 14.75 |
| Quick Ratio | 64.07 | 32.58 | 14.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $893.18 Million | $480.41 Million | $98.81 Million |
Enliven Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Enliven Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.60 |
| Latest Market Cap to Assets Ratio | 6.81 |
| Asset Growth Rate (YoY) | 46.2% |
| Total Assets | $476.17 Million |
| Market Capitalization | $3.24 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Enliven Therapeutics Inc.'s assets at a significant premium (6.81x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Enliven Therapeutics Inc.'s assets grew by 46.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual total assets of Enliven Therapeutics Inc. from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $476.17 Million | +46.17% |
| 2024-12-31 | $325.76 Million | +19.82% |
| 2023-12-31 | $271.87 Million | +226.38% |
| 2022-12-31 | $83.30 Million | -26.50% |
| 2021-12-31 | $113.33 Million | +24.75% |
| 2020-12-31 | $90.84 Million | +172.82% |
| 2019-12-31 | $33.30 Million | +332.16% |
| 2018-12-31 | $7.71 Million | -24.63% |
| 2017-12-31 | $10.22 Million | -- |
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more